Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582113 · ClinicalTrials.gov registry record · Early Phase 1
Cognizin Citicoline Dosing in a Healthy Adolescent Male Population
A Early Phase 1 study of Neurocognitive Improvement, sponsored by Deborah Yurgelun-Todd.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT01582113 is a Early Phase 1 study of Neurocognitive Improvement that has completed, run by Deborah Yurgelun-Todd. The registered enrollment target is 84 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01582113, a Early Phase 1 study of Neurocognitive Improvement, has completed, sponsored by Deborah Yurgelun-Todd.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the functional effects of Citicoline, a natural supplement, when administered for a duration of four weeks (28 days) to non-psychiatric adolescent male participants. The investigators hypothesize that citicoline will provide cognitive benefits to this population after 28 days of supplementation.
Conditions Studied
Interventions
- DRUG Citicoline
- OTHER Microcrystalline Cellulose
Study Locations (1)
Utah
- The Brain Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-06 |
| Est. Completion | 2017-05-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01582113
The ClinicalTrials.gov registry entry for NCT01582113 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deborah Yurgelun-Todd, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neurocognitive Improvement appearing as the primary indexed condition, and to 2 interventions - of which Citicoline is the first listed.
NCT01582113 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT01582113 about?
NCT01582113 is a clinical study titled "Cognizin Citicoline Dosing in a Healthy Adolescent Male Population". To determine the functional effects of Citicoline, a natural supplement, when administered for a duration of four weeks (28 days) to non-psychiatric adolescent male participants. The investigators hypothesize that citicoline will provide cognitive benefits to this population after 28 days of supplem...
What is the current status of trial NCT01582113?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 84 participants. The study started on 2012-06. Estimated completion is 2017-05-24.
What conditions does trial NCT01582113 study?
This clinical trial studies the following conditions: Neurocognitive Improvement.
What interventions are being tested in trial NCT01582113?
The interventions under investigation include: Citicoline (DRUG), Microcrystalline Cellulose (OTHER).
Who is sponsoring clinical trial NCT01582113?
This trial is sponsored by Deborah Yurgelun-Todd, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01582113 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.